By Josh White
Date: Friday 06 Dec 2024
(Sharecast News) - Syncona announced positive three-month interim results from the phase two 'DAWN' trial conducted by its portfolio company Beacon Therapeutics on Friday.
By Josh White
Date: Thursday 14 Nov 2024
(Sharecast News) - Syncona announced the launch of Slingshot Therapeutics, a new portfolio company and accelerator dedicated to developing early-stage life science programs sourced from academia, on Thursday.
By Josh White
Date: Monday 11 Nov 2024
(Sharecast News) - Life science investor Syncona announced on Monday that its portfolio company Autolus Therapeutics has received US Food and Drug Administration (FDA) approval for Aucatzyl (obe-cel), a CAR T-cell therapy developed for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (r/r B-ALL).
Currency | UK Pounds |
Share Price | 102.60p |
Change Today | 0.60p |
% Change | 0.59 % |
52 Week High | 130.60 |
52 Week Low | 99.50 |
Volume | 452,007 |
Shares Issued | 628.90m |
Market Cap | £645.26m |
Beta | 0.62 |
RiskGrade | 291 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 2 |
Buy | 1 |
Neutral | 1 |
Sell | 0 |
Strong Sell | 0 |
Total | 4 |
Latest | Previous | |
---|---|---|
Final | Final | |
Ex-Div | 21-Jun-18 | 20-Jul-17 |
Paid | 30-Jul-18 | 23-Aug-17 |
Amount | 2.30p | 2.30p |
Time | Volume / Share Price |
16:35 | 40,867 @ 102.60p |
16:35 | 1 @ 102.60p |
16:35 | 3,366 @ 102.60p |
16:35 | 2,309 @ 102.60p |
16:35 | 345 @ 102.60p |
You are here: research